Article
Gastroenterology & Hepatology
Man-Fung Yuen, Danny Ka-Ho Wong, Thomas Schluep, Ching-Lung Lai, Carlo Ferrari, Stephen Locarnini, Regina Cheuk-Lam Lo, Robert G. Gish, James Hamilton, Christine Wooddell, Lung Yi Mak, Bruce D. Given
Summary: The study investigated the serological, virological, and histological profiles in chronic HBV patients treated with multiple dose ARC-520. Results showed sustained and profound reductions in viral antigens and HBV RNA, with achievable HBsAg seroclearance. Immune activation was observed in some patients, and HBcAg staining was negative in all biopsied patients.
Article
Gastroenterology & Hepatology
Jung Woo Shin, Joonho Jeong, Seok Won Jung, Seung Bum Lee, Bo Ryung Park, Min-Ju Kim, Eun Ji Park, Neung Hwa Park
Summary: This study compared the efficacy of ETV and TDF in CHB patients and found that there was no significant difference in the risk of HCC and death or transplantation between ETV and TDF after adjusting for adherence and MVR in all patients and propensity score-matched cohorts.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Feng Su, Kristin Berry, George N. Ioannou
Summary: This study found no difference in the risk of HCC between patients with CHB treated with ETV and TDF, supporting the current guideline recommendations that both agents are appropriate first-line options for the treatment of CHB.
Article
Gastroenterology & Hepatology
Zhong-Bin Li, Le Li, Xiao-Xia Niu, Song-Hai Chen, Yi-Ming Fu, Chun-Yan Wang, Yan Liu, Qing Shao, Guofeng Chen, Dong Ji
Summary: The study aimed to evaluate the effectiveness and safety of switching from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) in ETV-treated patients with low-level viraemia (LLV). Results showed that switching to TAF was safer and superior to continuing ETV in terms of virological and biochemical benefits. Both therapies were well tolerated and had satisfying renal safety.
LIVER INTERNATIONAL
(2021)
Article
Immunology
Guanghua Rong, Yongping Chen, Zujiang Yu, Qin Li, Jingfeng Bi, Lin Tan, Dedong Xiang, Qinghua Shang, Chunliang Lei, Liang Chen, Xiaoyu Hu, Jing Wang, Huabao Liu, Wei Lu, Yan Chen, Zheng Dong, Wenlin Bai, Eric M. Yoshida, Nahum Mendez-Sanchez, Ke-Qin Hu, Xingshun Qi, Yongping Yang
Summary: Addition of Biejia-Ruangan (BR) to the current standard treatment with entecavir (ETV) can significantly increase rates of fibrosis regression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Oncology
Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
Summary: This study found that ETV and TDF treatments were associated with significantly lower risks of HCC in antiviral treatment-naive CHB patients. However, there was no significant difference in HCC incidence between ETV and TDF treatments regardless of the presence of preexisting cirrhosis.
Article
Gastroenterology & Hepatology
Seung Kak Shin, Hyung Joon Yim, Jeong Han Kim, Chan Uk Lee, Jong Eun Yeon, Sang Jun Suh, Young Kul Jung, Yun Soo Kim, Ju Hyun Kim, Oh Sang Kwon
Summary: This study found that partial virological response and higher FIB-4 index after 2 years of entecavir therapy were independent risk factors for hepatocellular carcinoma in patients with hepatitis B virus-associated cirrhosis. Efforts to achieve a complete virological response and reduce the FIB-4 index should be made to reduce the risk of HCC.
Article
Medicine, Research & Experimental
Aline Marcia Marques Braz, Fernanda Cristina Winckler, Larissa Sarri Binelli, Luis Guilherme Chimeno, Lia Beatriz Mantovani Lopes, Rodrigo Santos Lima, Rafael Plana Simoes, Rejane Maria Tommasini Grotto, Marjorie de Assis Golim, Giovanni Faria Silva
Summary: In cirrhotic patients with chronic hepatitis C, the most important biomarkers for predicting regression are TCD4+ lymphocytes. Non-regressors (NR) have lower levels of liver stiffness since baseline compared to regressors (R), while NK cells are increased in NR. The differences in the profile of circulating immune cells between R and NR allow for the development of a predictive model for regression of liver stiffness after SVR, although further validation in larger patient cohorts is needed.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Roni Atalay, Suleyman Sayar, Fatma Gulcicek Ayranci, Suheda Cakmak, Ibrahim Halil Tanboga, Levent Doganay, Kamil Ozdil
Summary: Hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.
TURKISH JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Gastroenterology & Hepatology
Ming Yang, Lai Wei
Summary: Hepatitis B virus (HBV) infection and nonalcoholic fatty liver disease (NAFLD) are two major causes of chronic liver disease (CLD) that can cause liver cirrhosis and hepatocellular carcinoma (HCC). It is becoming increasingly common in Asia to have concurrent NAFLD in chronic HBV infection. Although CHB patients tend to have a lower prevalence and incidence of NAFLD than the general population, concurrent NAFLD among CHB patients is still common and has an upward trend over time.
LIVER INTERNATIONAL
(2022)
Review
Gastroenterology & Hepatology
Xuefeng Ma, Shousheng Liu, Mengke Wang, Yifen Wang, Shuixian Du, Yongning Xin, Shiying Xuan
Summary: The study found that the virological response in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) was significantly superior to those treated with entecavir (ETV), and the therapeutic effect of TDF+ETV was also better than TDF alone.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Chien-Hung Chen, Cheng-Yuan Peng, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu
Summary: This study compared the rates of HBsAg loss after discontinuation of entecavir and tenofovir disoproxil fumarate in patients with chronic hepatitis B. The results showed that patients who discontinued TDF had higher risks of virological and clinical relapse, as well as retreatment, compared to those who discontinued entecavir.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Immunology
Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao
Summary: This study investigated the factors associated with persistent viremia in patients with chronic hepatitis B receiving long-term antiviral therapy, and found that baseline HBV DNA level, Anti-HBc level, and HBeAg seropositivity were associated with persistent viremia.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Xiaomo Wang, Yu Chen, Manman Xu, Kailiang Cheng, Xiaoman Duan, Wei Liao, Yanhong Wang, Ying Lu, Zhongping Duan, Li Wang
Summary: Among entecavir-treated chronic hepatitis B patients, those without maintaining virologic response are at higher risk of hepatocellular carcinoma, especially those with cirrhosis or a high predicted HCC score. For patients maintaining virologic response, the trajectories of ALT after response can indicate different risks of HCC.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Immunology
Yao-Chun Hsu, Ming-Lun Yeh, Grace Lai-Hung Wong, Chien-Hung Chen, Cheng-Yuan Peng, Maria Buti, Masaru Enomoto, Qing Xie, Huy Trinh, Carmen Preda, Li Liu, Ka-Shing Cheung, Yee Hui Yeo, Joseph Hoang, Chung-Feng Huang, Mar Riveiro-Barciela, Ritsuzo Kozuka, Doina Istratescu, Pei-Chien Tsai, Elena Vargas Accarino, Dong-Hyun Lee, Jia-Ling Wu, Jee Fu Huang, Chia-Yen Dai, Ramsey Cheung, Wan-Long Chuang, Man-Fung Yuen, Vincent Wai-Sun Wong, Ming-Lung Yu, Mindie H. Nguyen
Summary: In patients with chronic hepatitis B treated with ETV or TDF, the occurrence of HBsAg seroclearance is rare and is associated with low-level viremia, elevated alanine aminotransferase levels, bilirubin levels, and fatty liver.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Sylvia M. Brakenhoff, Margo J. H. van Campenhout, Annemiek A. van der Eijk, Willem P. Brouwer, Florian van Bommel, Bettina E. Hansen, Thomas Berg, Harry L. A. Janssen, Robert A. de Man, Milan J. Sonneveld
Summary: The study aimed to investigate the relationship between off-treatment ALT flares and virological outcomes, as well as to explore whether serum levels of novel biomarkers at the end of treatment can predict flares. The results showed that ALT flares were associated with decreased sustained response rates, and higher levels of HBsAg, HBV RNA, and HBcrAg were associated with an increased risk of flares.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Review
Virology
Nadjet Lebsir, Fabien Zoulim, Boyan Grigorov
Summary: Heparanase-1 is an important enzyme involved in viral infections and cancer, and its inhibitors can be used as both anti-cancer drugs and antiviral agents, potentially solving drug resistance issues in current antiretroviral therapies.
Article
Gastroenterology & Hepatology
Maria Paola Anolli, Elisabetta Degasperi, Lena Allweiss, Angelo Sangiovanni, Marco Maggioni, Caroline Scholtes, Valerie Oberhardt, Christoph Neumann-Haefelin, Maura Dandri, Fabien Zoulim, Pietro Lampertico
Summary: Bulevirtide has received conditional approval from the EMA for treating chronic hepatitis delta, but the optimal duration of therapy remains unknown. In this study, a patient with compensated cirrhosis and esophageal varices achieved hepatitis delta cure after 3 years of bulevirtide monotherapy. Virological and biochemical responses were maintained during the 72-week off-therapy follow-up, and significant improvements were observed in liver biopsy results.
JOURNAL OF HEPATOLOGY
(2023)
Article
Virology
Caroline Charre, Hadrien Regue, Paul Deny, Laurence Josset, Isabelle Chemin, Fabien Zoulim, Caroline Scholtes
Summary: This study presents a workflow to amplify, sequence, and analyze the whole HDV genome in a single fragment. The HDV genome was successfully amplified and fully sequenced, allowing accurate subtyping and identification of a new HDV genotype 1 subtype. This workflow overcomes genome assembly issues and helps to identify modifications throughout the whole HDV genome.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Gastroenterology & Hepatology
Clemence Moreau, Marine Roux, Jeremie Riou, Clemence M. Canivet, Etienne Audureau, Clovis Lusivika-Nzinga, Pierre Nahon, Fabrice Carrat, Jerome Boursier
Summary: This study aimed to evaluate whether the dynamics of multiple measurements of simple parameters after sustained viral response (SVR) enable the development of a personalized prediction of prognosis in patients with hepatitis C virus (HCV) chronic infection. The study found that FIB4 was a biomarker associated with liver-related complications (LRC) occurrence after SVR. The results suggest that dynamic modeling using repeated measurements of simple parameters predicts the individual residual risk of LRC and improves personalized medicine after SVR in HCV patients.
JOURNAL OF VIRAL HEPATITIS
(2023)
Article
Gastroenterology & Hepatology
Armando A. Roca A. Suarez, Enkhtuul Batbold, Birke Bartosch, Naranjargal Dashdorj, Barbara Testoni, Fabien Zoulim
Summary: Hepatitis delta virus (HDV) is a satellite RNA virus that requires hepatitis B virus (HBV) for replication. Co-infection with HDV/HBV leads to faster disease progression compared to HBV mono-infection. Developing antiviral therapies targeting HDV is crucial. Evaluating promising HDV-specific drugs and combination therapies, as well as exploring anti-HBV drugs with potential effects against HDV, are key areas of research.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Jordan J. Feld, Anna S. Lok, Fabien Zoulim
Summary: Current therapy for chronic hepatitis B rarely achieves a functional cure, but novel treatments are being developed. Understanding the mechanisms of hepatitis B virus persistence has helped identify new treatment targets and evaluate novel agents in clinical trials. Combining different agents appears to be a promising strategy to reduce viral replication, invigorate immune responses, and induce specific adaptive immune responses.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Infectious Diseases
Lorin Begre, Anders Boyd, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Charles Beguelin, Juergen K. Rockstroh, Huldrych F. Guenthard, Alexandra Calmy, Matthias Cavassini, Marcel Stoeckle, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Fabien Zoulim, Gilles Wandeler, Andri Rauch, Swiss HIV Cohort Study SHCS
Summary: In HIV patients with HBsAg loss, qHBsAg levels decline rapidly at the beginning and then show diverse trajectories during long-term tenofovir therapy. In patients without HBsAg loss, qHBsAg levels remain relatively stable over time.
Letter
Gastroenterology & Hepatology
Tangui Barre, David Zucman, Fabienne Marcellin, Clemence Ramier, Camelia Protopopescu, Raphaelle Tardieu, Karine Ory, Dominique Salmon-Ceron, Patrizia Carrieri
JOURNAL OF VIRAL HEPATITIS
(2023)
Review
Gastroenterology & Hepatology
Ievgeniia Chicherova, Charlotte Hernandez, Fanny Mann, Fabien Zoulim, Romain Parent
Summary: The liver is a neurovascular organ that develops various chronic liver diseases (CLD). Axon guidance cues (AGCs) play a role in the physiological development of the nervous system, but their expression can also be reinduced in diseases such as CLD. This review discusses the impact of AGCs on fibrosis regulation, immune functions, viral/host interactions, angiogenesis, and cell growth in CLD and HCC, and proposes future research directions.
LIVER INTERNATIONAL
(2023)
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Tarik Asselah, Ira M. Jacobson, Maurizia Rossana Brunetto, Harry L. A. Janssen, Tetsuo Takehara, Jin Lin Hou, Thomas N. Kakuda, Tom Lambrecht, Maria Beumont, Ronald Kalmeijer, Carine Guinard-Azadian, Cristiana Mayer, John Jezorwski, Thierry Verbinnen, Oliver Lenz, Umesh Shukla, Michael Biermer
Summary: This study evaluated the efficacy and safety of JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379) in combination with nucleos(t)ide analogues for the treatment of chronic hepatitis B. The results showed that a higher proportion of patients in the JNJ-3989 dual and triple groups met the nucleos(t)ide analogue-stopping criteria at 48 weeks, with good safety profile.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Microbiology
Rayana Maryse Toye, Carmen Luisa Loureiro, Rossana Celeste Jaspe, Fabien Zoulim, Flor Helene Pujol, Isabelle Chemin
Summary: HBV genotypes E to J are understudied and have specific distributions across different regions. Genotype F is the most divergent and has further subgenotypes. There is a lack of data from sub-Saharan Africa and Latin America due to under-representation in clinical and research cohorts.
Article
Gastroenterology & Hepatology
Barbara Testoni, Armando Andres Roca Suarez, Arianna Battisti, Marie-Laure Plissonnier, Marintha Heil, Thierry Fontanges, Francois Villeret, Yasmina Chouik, Massimo Levrero, Upkar Gill, Patrick Kennedy, Fabien Zoulim
Summary: This study validated the possibility to quantify cccDNA and assess its transcriptional activity in patients with chronic hepatitis B by combining FNA and droplet digital PCR. The use of FNA in clinical trials to evaluate the intrahepatic viral reservoir during the development of new antivirals and immunomodulatory agents is supported.
Article
Gastroenterology & Hepatology
Fabienne Marcellin, Sylvie Bregigeon-Ronot, Clemence Ramier, Camelia Protopopescu, Camille Gilbert, Vincent Di Beo, Claudine Duvivier, Morgane Bureau-Stoltmann, Eric Rosenthal, Linda Wittkop, Dominique Salmon-Ceron, Patrizia Carrieri, Philippe Sogni, Tangui Barre
Summary: This study aimed to investigate the prevalence of moderate-to-severe depression in people living with HIV and HCV after successful HCV treatment, and identify associated socio-behavioral factors. Through descriptive and logistic regression analyses of data from 398 participants, it was found that 23.9% of HCV-cured individuals had moderate-to-severe depression. Female sex, unhealthy alcohol use, sedentary lifestyle, and unhealthy eating behaviors were associated with increased odds of moderate-to-severe depression.
Letter
Gastroenterology & Hepatology
Tobias Boettler, Aleksander Krag, Thomas Berg
JOURNAL OF HEPATOLOGY
(2023)